Category - Markets

Maxim Group downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “hold” from “buy” and removed its price target after Keryx and Akebia Therapeutics (NASDAQ:AKBA) unveiled a definitive agreement to merge in an all-stock...

H.C. Wainwright launched coverage of AquaBounty Technologies (NASDAQ:AQB) with a “buy” rating and a “conservative” $3.75 price target. The stock closed at $2.99 on June 27. AquaBounty is focused on enhancing...

BTIG downgraded TransEnterix (NASDAQ:TRXC) to “neutral” from “buy,” citing a tripling in the stock price, which has exceeded its price target of $3.50. The stock closed at $5.84 on June 27. “We continue to like the...

The common shares of Imagin Medical (CSE:IME; OTC:IMEXF) were approved for uplisting from the Pink Open Market to the OTCQB Venture Market, with the same symbol, IMEXF, effective at the open on June 28, 2018. “Uplisting...

BTIG launched coverage of Zosano Pharma (NASDAQ:ZSAN) with a “buy” rating and 12-month price target of $19. The stock closed at $3.80 on June 27. Zosano is focused on the development of therapeutics using its ADAM...

Ladenburg Thalmann initiated coverage of Palatin Technologies (NYSE MKT:PTN) with a “buy” rating and $3 price target. The stock closed at $1.05 on June 26. Palatin’s lead asset, bremelanotide (BMT), is a melanocortin...

Ladenburg Thalmann launched coverage of Tocagen (NASDAQ: TOCA) with a “buy” rating and $20 price target. The stock closed at $8.81 on June 26. TOCA is developing a novel viral gene therapy for cancer and has developed a...

Analysts for Stifel and Canaccord Genuity raised their price targets for AtriCure (NASDAQ:ATRC) after an analyst day meeting highlighted the significant penetration opportunity in the atrial fibrillation (AF) market...

Maxim Group initiated coverage of IntelGenx (OTCQX:IGXT; TSXV:IGX) with a “buy” rating and price target of $3. The stock closed at 78 cents on June 26. Analyst Jason McCarthy writes that the company’s VersaFilm is a...

H.C. Wainwright initiated coverage of Avenue Therapeutics (NASDAQ:ATXI) with a “buy” rating and price target of $11. The stock closed at $3.77 on June 25. Avenue Therapeutics is focused on the acute care hospital...